Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Shoki Okubo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Endoglin, Myofibroblasts. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Carcinoma‐associated fibroblasts (CAFs), which are abundant in the tumor microenvironment, influence cancer hallmarks. We previously described transforming growth factor‐β (TGF‐β)–Smad2/3 signaling as being activated in myofibroblastic CAFs (myCAFs) in an autocrine fashion by increasing TGF‐β production. However, factors regulating such autocrine TGF‐β signaling remain poorly understood. Herein, we show that the abundance of endoglin (ENG), a TGF‐β superfamily coreceptor expressed on human breast myCAFs, is significantly associated with poorer outcomes of breast cancer patients. Inhibition of ENG expression on myCAFs not only suppressed the TGF‐β–Smad2/3 pathway and TGF‐β1 expression but also attenuated the ability of myCAF to promote primary tumor growth and metastasis. Mechanistically, ENG facilitates TGF‐β–Smad2/3 signaling in myCAFs, presumably through association with a TGF‐β ligand–receptor complex, leading to self‐stimulating TGF‐β1 production. Stromal TGF‐β1, in turn, induces partial epithelial–mesenchymal transition in cancer cells in a paracrine manner, resulting in suppression of primary tumor growth and promotion of invasion and metastasis. ENG‐primed TGF‐β autocrine signaling also produces other factors that could mediate primary tumor growth promotion by myCAFs. Collectively, these findings suggest that ENG‐primed TGF‐β autocrine and paracrine signaling mediates tumor‐ and metastasis‐promoting abilities of myCAFs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Department of Pathology and Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
- Department of Immunological Diagnosis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Center for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Japan.
ORCID-Profile: Shoki Okubo, Yoshihiro Mezawa, Ahmet Acar, Takuya Shirakihara, Akira Orimo
Zitieren
APA
Okubo, S., Mezawa, Y., Wang, Z., Acar, A., Ito, Y., Takano, A., Miyagi, Y., Yokose, T., Yamashita, T., Daigo, Y., Shirakihara, T., & Orimo, A. (2025). Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas. Molecular Oncology. https://doi.org/10.1002/1878-0261.70074
Vancouver
Okubo S, Mezawa Y, Wang Z, Acar A, Ito Y, Takano A, et al. Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas. Molecular Oncology. 2025. doi:10.1002/1878-0261.70074
BibTeX
@article{Okubo2025,
author = {Okubo, Shoki and Mezawa, Yoshihiro and Wang, Zixu and Acar, Ahmet and Ito, Yasuhiko and Takano, Atsushi and Miyagi, Yohei and Yokose, Tomoyuki and Yamashita, Toshinari and Daigo, Yataro and Shirakihara, Takuya and Orimo, Akira},
title = {Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70074}
}
EUVIMED